RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321

Last updated date
Study Location
Pfizer Investigational Site
Anniston, Alabama, 36207, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postherpetic Neuralgia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female of any race, at least 18 years of age.

- Patients must have pain present for more than 3 months after healing of the herpes zoster skin rash.

- Has a pain score at screening that qualifies.

- Completes at least 3 average daily pain diaries during the 3 days prior to randomization and has an average pain level that qualifies.

- Body Mass Index less than or equal to 39 kg/m2.

- If female, is post-menopausal, surgically sterile, or uses adequate contraception consisting of 2 forms of birth control, one of which must be barrier method, is not lactating, and is not breastfeeding.

- Male patients must agree that female spouses/partners will use contraception as defined above or be of nonchildbearing potential (post-menopausal or surgically sterile).

- Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

- Patients must consent in writing to participate in the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients who cannot discontinue the use of other pain medications during the screening
period and during the study.


- Disqualifying scores on questionnaires.


- Other moderate to severe pain from other conditions.


- History of allergic or anaphylactic reaction to antibodies.


- Use of biologics, including any live vaccines within 3 months of the week prior to the
baseline visit.


- Unable to use acetaminophen.


- Disqualify laboratory values, Hepatitis B or C or HIV.


- Patients that have had a stroke or TIAs, dementia, epilepsy or seizures, or peripheral
neuropathy from other conditions.


- Significant cardiac disease within 3 months of the study such as angina, heart attack,
congestive heart failure, and other cardiac problems.


- Cancer other than basal cell or squamous cell carcinoma.


- Fails a urine test for illegal drugs including prescription drugs without a
prescription.


- Plans for surgery during the study.


- History of alcoholism or drug abuse in the past two years.


- Surgery for post-herpetic neuralgia.


- Any condition that the investigator feels would put the safety of the patient at risk.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Postherpetic NeuralgiaRN624 For Pain Of Post-Herpetic Neuralgia NCT00568321
  1. Anniston, Alabama
  2. Litchfield Park, Arizona
  3. Phoenix, Arizona
  4. Atlantis, Florida
  5. Clearwater, Florida
  6. Largo, Florida
  7. Miami, Florida
  8. Palm Beach Gardens, Florida
  9. Sunrise, Florida
  10. Tampa, Florida
  11. Topeka, Kansas
  12. Towson, Maryland
  13. N. Dartmouth, Massachusetts
  14. Ann Arbor, Michigan
  15. Edina, Minnesota
  16. St Louis, Missouri
  17. Asheville, North Carolina
  18. Cleveland, Ohio
  19. Dayton, Ohio
  20. Kettering, Ohio
  21. Altoona, Pennsylvania
  22. Duncansville, Pennsylvania
  23. Bryan, Texas
  24. Dallas, Texas
  25. Houston, Texas
  26. San Antonio, Texas
  27. Richmond, Virginia
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postherpetic NeuralgiaPH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia NCT00614705
  1. Vina del Mar, V Region
  2. Moscow,
  3. St. Petersburg,
  4. St. Petersburg,
  5. Yaroslavl,
  6. Cadiz,
  7. Madrid,
  8. Ourense,
  9. Sevilla,
  10. Valencia,
  11. Linkoping,
  12. Stockholm,
  13. Stockholm,
  14. Dnipropetrovsk,
  15. Donetsk,
  16. Kharkiv,
  17. Kharkiv,
  18. Kharkiv,
  19. Kyiv,
  20. Odessa,
  21. Simferopol,
  22. Bexhill on Sea, East Sussex
  23. Blackpool, Lancashire
  24. Weybridge, Surrey
  25. Solihull,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postherpetic NeuralgiaA 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia NCT00394901
  1. Nagoya, Aichi
  2. Ichikawa, Chiba
  3. Urayasu, Chiba
  4. Kasuga, Fukuoka
  5. Kasuya-gun, Fukuoka
  6. Maebaru, Fukuoka
  7. Maebashi, Gunma
  8. Takasaki, Gunma
  9. Asahikawa, Hokkaido
  10. Sapporo, Hokkaido
  11. Akashi, Hyogo
  12. Amagasaki, Hyogo
  13. Himeji, Hyogo
  14. Kobe, Hyogo
  15. Nishinomiya, Hyogo
  16. Tsuchiura, Ibaraki
  17. Sagamihara, Kanagawa
  18. Yokohama, Kanagawa
  19. Sendai, Miyagi
  20. Beppu, Ohita
  21. Kishiwada, Osaka
  22. Takatsuki, Osaka
  23. Kawaguchi, Saitama
  24. Kitamoto, Saitama
  25. Tokorozawa, Saitama
  26. Adachi-ku, Tokyo
  27. Arakawa-ku, Tokyo
  28. Bunkyo-ku, Tokyo
  29. Edogawa-ku, Tokyo
  30. Mitaka, Tokyo
  31. Nakano-ku, Tokyo
  32. Shinagawa-ku, Tokyo
  33. Shinjuku-ku, Tokyo
  34. Suginami-ku, Tokyo
  35. Toshima-ku, Tokyo
  36. Fukuoka,
  37. Fukushima,
  38. Osaka,
  39. Saitama,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postherpetic NeuralgiaPilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia NCT01603394
  1. Leesburg, Florida
  2. Lexington, Kentucky
  3. Raleigh, North Carolina
  4. Jekintown, Pennsylvania
  5. Senftenberg, A-3541
  6. Wien,
  7. Schwerin,
  8. Pretoria, Gauteng
  9. Paarl, Western Cape
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE RN624 For Pain Of Post-Herpetic Neuralgia
Official Title  ICMJE A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of RN624 In Adult Patients With Post-Herpetic Neuralgia
Brief Summary This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Neuralgia, Postherpetic
Intervention  ICMJE
  • Drug: RN624
    50 mcg/kg
  • Drug: RN624
    200 mcg/kg
  • Drug: Placebo
    placebo
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: RN624
  • Active Comparator: 2
    Intervention: Drug: RN624
  • Placebo Comparator: 3
    Intervention: Drug: Placebo
Publications * Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, Verburg KM, Dyck PJ. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015 Jun;16(6):1163-76. doi: 10.1111/pme.12677. Epub 2015 Jan 16.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 13, 2009)
99
Original Estimated Enrollment  ICMJE
 (submitted: December 5, 2007)
129
Actual Study Completion Date  ICMJE January 2009
Actual Primary Completion Date December 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female of any race, at least 18 years of age.
  • Patients must have pain present for more than 3 months after healing of the herpes zoster skin rash.
  • Has a pain score at screening that qualifies.
  • Completes at least 3 average daily pain diaries during the 3 days prior to randomization and has an average pain level that qualifies.
  • Body Mass Index less than or equal to 39 kg/m2.
  • If female, is post-menopausal, surgically sterile, or uses adequate contraception consisting of 2 forms of birth control, one of which must be barrier method, is not lactating, and is not breastfeeding.
  • Male patients must agree that female spouses/partners will use contraception as defined above or be of nonchildbearing potential (post-menopausal or surgically sterile).
  • Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Patients must consent in writing to participate in the study.

Exclusion Criteria:

  • Patients who cannot discontinue the use of other pain medications during the screening period and during the study.
  • Disqualifying scores on questionnaires.
  • Other moderate to severe pain from other conditions.
  • History of allergic or anaphylactic reaction to antibodies.
  • Use of biologics, including any live vaccines within 3 months of the week prior to the baseline visit.
  • Unable to use acetaminophen.
  • Disqualify laboratory values, Hepatitis B or C or HIV.
  • Patients that have had a stroke or TIAs, dementia, epilepsy or seizures, or peripheral neuropathy from other conditions.
  • Significant cardiac disease within 3 months of the study such as angina, heart attack, congestive heart failure, and other cardiac problems.
  • Cancer other than basal cell or squamous cell carcinoma.
  • Fails a urine test for illegal drugs including prescription drugs without a prescription.
  • Plans for surgery during the study.
  • History of alcoholism or drug abuse in the past two years.
  • Surgery for post-herpetic neuralgia.
  • Any condition that the investigator feels would put the safety of the patient at risk.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00568321
Other Study ID Numbers  ICMJE A4091005
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP